Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Amon Asgharpour

Showing results (1-10 of 56) with videos related to

Pageof 6
Sort By:
Current Opinion in Gastroenterology|February 15, 2026
The alcohol-associated hepatitis treatment landscapeHanna Blaney, Amon Asgharpour
Methods in Molecular Biology (Clifton, N.J.)|February 25, 2022
Generation of a Diet-Induced Mouse Model of Nonalcoholic Fatty Liver DiseaseAmon Asgharpour, Arun J Sanyal
Gastroenterology & Hepatology|May 26, 2021
Smoking and Liver DiseaseStephanie M Rutledge, Amon Asgharpour
Hepatology International|August 31, 2015
Bile acids: emerging role in management of liver diseasesAmon Asgharpour, Divya Kumar, Arun Sanyal
Gastroenterology Clinics of North America|February 9, 2020
Pharmacologic Treatment Strategies for Nonalcoholic SteatohepatitisJames Philip G Esteban, Amon Asgharpour
ACG Case Reports Journal|February 5, 2024
Spontaneous Hepatic Hemorrhage Causing Acute Liver Failure Requiring Liver TransplantKrunal Shukla, Rahul Chaudhari, Amon Asgharpour
Translational Gastroenterology and Hepatology|July 27, 2022
Evaluation of liver transplant candidates with non-alcoholic steatohepatitisJames Philip G Esteban, Amon Asgharpour
Clinical and Experimental Gastroenterology|September 17, 2013
Adalimumab treatment in Crohn's disease: an overview of long-term efficacy and safety in light of the EXTEND trialAmon Asgharpour, Jianfeng Cheng, Stephen J Bickston
Translational Gastroenterology and Hepatology|January 7, 2021
Basic science to clinical trials in non-alcoholic fatty liver disease and alcohol-related liver disease: collaboration with industryAmon Asgharpour, Amreen Dinani, Scott L Friedman
Infection and Immunity|July 26, 2005
Resistance to intestinal Entamoeba histolytica infection is conferred by innate immunity and Gr-1+ cellsAmon Asgharpour, Carol Gilchrist, Duza Baba, et al.
Pageof 6

Showing results (1-10 of 56) with videos related to

Sort By:
Pageof 6
Current Opinion in Gastroenterology|February 15, 2026
The alcohol-associated hepatitis treatment landscapeHanna Blaney, Amon Asgharpour
Methods in Molecular Biology (Clifton, N.J.)|February 25, 2022
Generation of a Diet-Induced Mouse Model of Nonalcoholic Fatty Liver DiseaseAmon Asgharpour, Arun J Sanyal
Gastroenterology & Hepatology|May 26, 2021
Smoking and Liver DiseaseStephanie M Rutledge, Amon Asgharpour
Hepatology International|August 31, 2015
Bile acids: emerging role in management of liver diseasesAmon Asgharpour, Divya Kumar, Arun Sanyal
Gastroenterology Clinics of North America|February 9, 2020
Pharmacologic Treatment Strategies for Nonalcoholic SteatohepatitisJames Philip G Esteban, Amon Asgharpour
ACG Case Reports Journal|February 5, 2024
Spontaneous Hepatic Hemorrhage Causing Acute Liver Failure Requiring Liver TransplantKrunal Shukla, Rahul Chaudhari, Amon Asgharpour
Translational Gastroenterology and Hepatology|July 27, 2022
Evaluation of liver transplant candidates with non-alcoholic steatohepatitisJames Philip G Esteban, Amon Asgharpour
Clinical and Experimental Gastroenterology|September 17, 2013
Adalimumab treatment in Crohn's disease: an overview of long-term efficacy and safety in light of the EXTEND trialAmon Asgharpour, Jianfeng Cheng, Stephen J Bickston
Translational Gastroenterology and Hepatology|January 7, 2021
Basic science to clinical trials in non-alcoholic fatty liver disease and alcohol-related liver disease: collaboration with industryAmon Asgharpour, Amreen Dinani, Scott L Friedman
Infection and Immunity|July 26, 2005
Resistance to intestinal Entamoeba histolytica infection is conferred by innate immunity and Gr-1+ cellsAmon Asgharpour, Carol Gilchrist, Duza Baba, et al.
Pageof 6